CuraTeQ Biologics

CuraTeQ Biologics is a biopharmaceutical company based in Hyderabad, India, specialising in the development and manufacturing of biosimilars and synthetic peptides. With a robust pipeline of 14 biosimilars, CuraTeQ boasts significant milestones, including three products filed with the European Medicines Agency (EMA), one with the Medicines and Healthcare products Regulatory Agency (MHRA), and four currently in global Phase 3 clinical trials. Their flagship product, Dazublys™, a Trastuzumab biosimilar, has received marketing authorisation in India and has been filed with the EMA. In addition, CuraTeQ operates Auro Peptides, its synthetic peptides manufacturing arm, which has filed 14 Drug Master Files (DMFs) with the US Food and Drug Administration (FDA), contributing to six Abbreviated New Drug Applications (ANDAs). The company also offers comprehensive Contract Development and Manufacturing Organisation (CDMO) services tailored to biopharmaceuticals.

Services include:
- Anatomical Therapeutic Chemical (ATC) Classification
- Active Pharmaceutical Ingredients (APIs)
- Biologics
- Contract Development and Manufacturing (CDMO)
- Packaging Equipment

CuraTeQ Biologics is committed to advancing the pharmaceutical landscape with high-quality products and services. For further information, please visit curateqbio.com.